Latest News and Press Releases

Phase 2 Proof-of-Concept study in TRD patients resistant to standard antidepressants suggests positive trend in efficacy.Potential first-in-class oral prolonged-release formulation of ketamine, KET01,...

Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in...

In-Licensing arrangement with the renowned Max Planck Society, extends patent protection for clinical research and strengthens Nelivabon and Cortibon developmental projects The Company has also...

MUNICH, Germany, Jan. 06, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “Company”), a clinical stage precision psychiatry biopharma company, pioneering the development of personalized...

--Appointment strengthens Company’s global management team, brings vast capital market expertise, unique network in the global financial community, and robust operational industry experience-- ...

MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by...

MUNICH, Germany, Nov. 02, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by...

MUNICH, Nov. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health ("HMNC" or the "company"), a clinical-stage biopharma company pioneering the development of personalized therapies powered by predictive...

Pioneering the first large-scale double-blind studies to test the combination of therapies and genetic companion diagnostics in the area of mental healthPartners with worldwide leading contract...

MUNICH, Germany, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by...